Jamieson Wellness Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Establishes 2021 Guidance

 

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX: JWEL) today reported financial results for its fourth quarter and year ended December 31, 2020. All amounts are expressed in Canadian dollars. Certain metrics, including those expressed on an adjusted basis, are non-IFRS measures. See "Non-IFRS Financial Measures" below.

 

  Highlights of Fourth Quarter 2020 Results versus Fourth Quarter 2019 Results  

 
  • Revenue increased 16.6% to $120.4 million;
  •  
  • Jamieson Brands revenue increased by 13.9%;
  •  
  • Adjusted EBITDA increased 14.6% to $29.4 million;
  •  
  • Net income was $15.4 million and adjusted net income increased 23.6% to $17.6 million; and
  •  
  • Earnings per diluted share were $0.37 and adjusted earnings per diluted share were $0.42.
  •  

  Highlights of Full Year 2020 Results versus Full Year 2019 Results  

 
  • Revenue increased 17.0% to $403.7 million;
  •  
  • Jamieson Brands revenue increased by 19.0%;
  •  
  • Adjusted EBITDA increased 15.9% to $88.0 million;
  •  
  • Net income was $41.6 million and adjusted net income increased 25.8% to $47.9 million; and
  •  
  • Earnings per diluted share were $1.01, and adjusted earnings per diluted share increased 21.1% to $1.16.
  •  

"We are pleased that consumers across Canada and around the world are choosing Jamieson in their quest for health and wellness," said Mark Hornick, President and Chief Executive Officer of Jamieson Wellness. "The COVID-19 pandemic has elevated health and wellness to become the top priority for consumers globally, and we are grateful for the role our brands play in supporting our consumers' foundational health. Throughout 2020, our existing consumers increased their daily compliance while broadening the selection of vitamins and supplements in their routines. Many new consumers have engaged with our brands for the first time, as shoppers look for quality products they can trust. We have seen these trends become more established through 2020 and look forward to building upon this baseline of growth in the coming year.

 

The COVID-19 pandemic also tested our Jamieson team's ability to navigate unprecedented challenges in a constantly changing environment. I am incredibly proud of how our team pulled together to ensure uninterrupted supply of our products when they were needed the most, while doing everything possible to maintain a healthy and safe working environment.

 

Entering 2021, we have solid momentum in all of our businesses and our scalable capacity ensures the Company remains well positioned to continue driving exceptional growth, delivering on our long-term vision to improve the world's health and wellness."

 

  Fourth Quarter 2020 Results  

 

Revenue increased 16.6% to $120.4 million in the fourth quarter of 2020 compared with $103.3 million in the fourth quarter of 2019 driven by 13.9% growth in Jamieson Brands and 25.3% growth in Strategic Partners.

 

Revenue in the Jamieson Brands segment increased by 13.9% or $10.9 million to $89.7 million. Demand remained high throughout the fourth quarter across the Company's domestic and international markets as consumers continue to emphasize immunity and general health. The Company's domestic Jamieson Brands sales increased by 13.7% in the fourth quarter, gaining share over competitors as the Company experienced steady point-of-sale growth across an expanding base. The Company's domestic results showed strong growth in e-commerce, food, drug and mass retail channels. The Company's international business increased 14.8% in the fourth quarter, which includes the expected timing of a shipment to China realized in the preceding quarter. Consumer demand for immunity products continues to be high across all of the Company's primary international markets with elevated shipments to Eastern Europe and the Middle East in the quarter.

 

Revenue in the Strategic Partners segment increased 25.3%, or $6.2 million to $30.6 million in the fourth quarter of 2020 reflecting timing factors related to new programs with the Company's largest soft-gel customer. This was partially offset by lower powder volumes from a strategic partner retail customer who emerged from Chapter 11 reorganization in the quarter.

 

Gross profit margin decreased by 300 basis points to 35.3% including a 130-basis point impact primarily from start-up costs associated with the Company's transition to a third-party logistics provider. Normalized gross profit margin of 36.6% was down 170 basis points including 60 basis points attributable to segment mix and 110 basis points mainly due to higher supply continuity costs related to COVID-19. Normalized gross profit margin in the Jamieson Brands segment decreased by 80 basis points to 44.8% as supply continuity costs including increased health and safety measures offset promotional and volume related efficiencies. Gross profit margin in Strategic Partners decreased by 170 basis points to 12.9%, primarily driven by customer mix and a reduction in volume and efficiency at the Company's powder facility and higher supply continuity costs related to COVID-19.

 

Selling, general and administrative ("SG&A") expenses increased by $1.0 million to $18.6 million in the fourth quarter of 2020. On a normalized basis, SG&A expenses increased $1.4 million to $18.1 million in the fourth quarter of 2020 driven by increased headcount to support the Company's worldwide and e-commerce expansion plans, higher variable compensation, and increased marketing investments. The Company incurred $0.6 million of costs related to COVID-19 in the fourth quarter of 2020 and the year-earlier period included $1.0 million of costs related to China initial set-up, supply chain optimization and cyber-security enhancements.

 

Earnings from operations increased by $2.4 million, or 11.8%, to $22.7 million in the fourth quarter of 2020 and operating margin decreased by 80 basis points to 18.9% as improvements in fixed costs as a percent of revenue partially offset factors that pressured gross profit margin during the quarter. On a normalized basis, earnings from operations increased by $3.6 million, or 16.9% in the fourth quarter of 2020 and operating margin was consistent at 20.7% compared with the fourth quarter of 2019.

 

Adjusted EBITDA increased 14.6% to $29.4 million in the fourth quarter of 2020 and adjusted EBITDA margin was 24.4% compared with 24.8% in the fourth quarter of 2019.

 

Interest expense and other financing costs decreased $0.6 million to $1.4 million in the fourth quarter of 2020 due to lower average borrowings and lower interest rates.

 

Net income for the fourth quarter of 2020 was $15.4 million compared with $13.2 million in the fourth quarter of 2019. Adjusted net income, which excludes all non-operating expenses and foreign exchange, increased $3.4 million, or 23.6%, to $17.6 million in the fourth quarter of 2020.

 

Adjusted net income excludes costs associated with share-based compensation, foreign exchange loss, business integration, COVID-19 related costs, other non-recurring expenses and related tax effects. A detailed reconciliation of reported net income to non-IFRS adjusted net income is included in the tables accompanying this release under the heading "Non-IFRS Financial Measures".

 

  Balance Sheet & Cash Flow  

 

The Company generated $18.7 million in cash from operations during the fourth quarter of 2020 compared with $13.0 million in the fourth quarter of 2019. Cash from operating activities before working capital considerations of $22.2 million was $4.0 million higher reflecting increased earnings. Cash invested in working capital decreased by $1.7 million due to the timing of payments and draw down of inventory stemming from strong shipments during the quarter. The Company's cash at December 31, 2020 was $1.2 million compared to $0.2 million on December 31, 2019. The Company ended the quarter with approximately $127.1 million in cash and available operating lines and total debt of $149.1 million.

 

On November 19, 2020, the Company declared a quarterly dividend of $0.125 per common share to holders of record as of December 1, 2020 and paid such dividend on December 15, 2020. The dividend payment was approximately $5.0 million in the aggregate.

 
                                                                                                
  Three months ended  
  December 31  
  ($ in 000's, except as otherwise noted)   

  2020  

 
 

  2019  

 
 

  $ Change  

 
 

  % Change  

 
 
Cash, beginning of period  

  3,144  

 
 

 

 
 

  4,153  

 
 

 

 
 

  (1,009  

 
 

  )  

 
 

  (24.3  

 
 

  %)  

 
Cash flows from (used in):
Operating activities  

18,744

 
 

 

 
 

12,996

 
 

 

 
 

5,748

 
 

 

 
 

44.2

 
 

%

 
Investing activities  

(4,220

 
 

)

 
 

(3,488

 
 

)

 
 

(732

 
 

)

 
 

(21.0

 
 

%)

 
Financing activities  

(16,502

 
 

)

 
 

(13,463

 
 

)

 
 

(3,039

 
 

)

 
 

(22.6

 
 

%)

 
  Cash, end of period   

  1,166  

 
 

 

 
 

  198  

 
 

 

 
 

  968  

 
 

 

 
 

  488.9  

 
 

  %  

 
 

  Fiscal 2021 Outlook  

 

The Company is introducing its revenue outlook for fiscal 2021 and anticipates revenue in a range of $421.0 to $438.0 million, which represents annual growth of 4.3% to 8.6%. The Company estimates adjusted EBITDA in a range of $95.0 to $100.0 million and adjusted diluted earnings per share in a range of $1.24 to $1.32.

 

This outlook reflects the following assumptions:

 
  • Jamieson Brands segment growth of between 4.0% and 8.0%, driven by the following:
    • Domestic branded revenues to grow between 2.0% and 5.0% including the impact of both pricing and volume expectations while lapping surge COVID-19 demand realized earlier in the pandemic.
    •  
    • International branded growth between 15.0% and 25.0% including headwinds resulting from foreign exchange. The increase reflects strong growth in China while sustaining a higher base in remaining international markets.
    •  
  •  
  • Revenue in the Strategic Partners segment is expected to increase between 5.0% to 10.0%
  •  
  • Normalized SG&A increases of 9% to 13% to expand e-commerce capabilities and support growth in international markets, including a $3.0 to $4.0 million investment in marketing primarily to support international markets and long-term growth opportunities in China
  •  
  • Interest expense of between $5.5 million to $6.0 million
  •  
  • Income tax rate of approximately 27.0%
  •  
  • A fully diluted share count of between 41.5 and 42.0 million shares
  •  

For additional details on the Company's fiscal 2021 outlook, including guidance for the first quarter of 2021, refer to the "Outlook" section in the management's discussion and analysis of financial condition and results of operations ("MD&A") for the three and twelve months ended December 31, 2020.

 

  Declaration of Fourth Quarter Dividend  

 

The Company announces today a cash dividend for the fourth quarter of 2020 of $0.125 per common share or approximately $5.0 million in the aggregate. The dividend will be paid on March 15, 2021 to all common shareholders of record at the close of business on March 5, 2021. The Company has designated this dividend as an "eligible dividend" for the purposes of the Income Tax Act (Canada).

 

  Leadership Transition  

 

Also announced today, Mark Hornick has decided to retire and Mike Pilato, President of Jamieson Canada, will advance to the role of President and CEO of Jamieson Wellness, effective June 1, 2021. The Board of Directors wish Mr. Hornick the very best in his retirement, and look forward to continuing to grow the Company under the leadership of Mr. Pilato. Details on this planned succession and ongoing transition can be found in a separate media release issued this afternoon.

 

  Consolidated Financial Statements and Management's Discussion and Analysis  

 

The Company's audited consolidated annual financial statements and accompanying notes as at and for the three and twelve months ended December 31, 2020 and related MD&A are available under the Company's profile on SEDAR at www.sedar.com and on the Investor Relations section of the Company's website at https://investors.jamiesonwellness.com .

 

  Conference Call  

 

Management will host a conference call to discuss the Company's fourth quarter 2020 results at 5:00 p.m. ET today, February 25, 2021. The call can be accessed live over the telephone by dialing 1-866-248-8441 from Canada and the U.S. or 1-323-289-6576 from international locations. Due to increased volumes of conference calls this quarter, please dial the conference call number 15 minutes prior to the start time. A replay will be available shortly after the call and can be accessed by dialing 1-844-512-2921 from Canada and the U.S. or 1-412-317-6671 from international locations. The passcode for the replay is 8052896 and it will be available until Thursday, March 11, 2021.

 

Interested parties may listen to a simultaneous webcast of the conference call by logging on via the Investor Relations section of the Company's website at   https://investors.jamiesonwellness.com   or directly at https://public.viavid.com/index.php?id=143519 . A replay of the webcast will be available for approximately 30 days following the call.

 

  About Jamieson Wellness  

 

Jamieson Wellness is dedicated to improving the world's health and wellness with its portfolio of innovative natural health brands. Established in 1922, Jamieson is the Company's heritage brand and Canada's #1 consumer health brand. Jamieson Wellness manufactures and markets sports nutrition products and specialty supplements under its Progressive, Precision and Iron Vegan brands. The Company also markets Smart Solutions by Lorna Vanderhaeghe, the #1 women's natural health focused brand in Canada. For more information please visit jamiesonwellness.com.

 

Jamieson Wellness' head office is located at 1 Adelaide Street East Suite 2200, Toronto, Ontario, Canada.

 

  Forward-Looking Information  

 

This press release may contain forward-looking information within the meaning of applicable securities legislation. Such information includes, but is not limited to, statements related to the Company's anticipated results and its outlook for its 2021 revenue, adjusted EBITDA and adjusted diluted earnings per share. Words such as "expect,", "anticipate", "intend,", "may,", "will", "estimate" and variations of such words and similar expressions are intended to identify such forward-looking information. This information reflects the Company's current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company's control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, the factors discussed under "Risk Factors" in the Company's Annual Information Form dated March 27, 2020 and under the "Risk Factors" section in the Company's MD&A filed today, February 25, 2021. This information is based on the Company's reasonable assumptions and beliefs in light of the information currently available to it and the statements are made as of the date of this press release. The Company does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law or regulatory authority.

 

The Company cautions that the list of risk factors and uncertainties is not exhaustive and other factors could also adversely affect the Company's results. Readers are urged to consider the risks, uncertainties and assumptions associated with these statements carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information. See "Forward-looking Information" and "Risk Factors" within the Company's MD&A for a discussion of the uncertainties, risks and assumptions associated with these statements.

 
                                                                                                                                                                                                                                                                                                                                                                                                                     
 

  Jamieson Wellness Inc.  

 

Consolidated Statements of Operations

 

In thousands of Canadian dollars, except share and per share amounts

 
 
 
 
  Three months ended    For the year ended  
  December 31    December 31  
 

  2020  

 
 

  2019  

 
 

  2020  

 
 

  2019  

 
 
  Revenue   

  120,369  

 
 

 

 
 

  103,253  

 
 

 

 
 

  403,661  

 
 

 

 
 

  344,980  

 
 

 

 
Cost of sales  

77,855

 
 

 

 
 

63,711

 
 

 

 
 

258,905

 
 

 

 
 

215,246

 
 

 

 
Gross profit  

42,514

 
 

 

 
 

39,542

 
 

 

 
 

144,756

 
 

 

 
 

129,734

 
 

 

 
 
  Gross profit margin   

  35.3  

 
 

  %  

 
 

  38.3  

 
 

  %  

 
 

  35.9  

 
 

  %  

 
 

  37.6  

 
 

  %  

 
 
Selling, general and administrative expenses  

18,624

 
 

 

 
 

17,637

 
 

 

 
 

76,259

 
 

 

 
 

69,942

 
 

 

 
Share-based compensation  

1,156

 
 

 

 
 

1,573

 
 

 

 
 

4,925

 
 

 

 
 

4,343

 
 

 

 
  Earnings from operations   

  22,734  

 
 

 

 
 

  20,332  

 
 

 

 
 

  63,572  

 
 

 

 
 

  55,449  

 
 

 

 
 
  Operating margin   

  18.9  

 
 

  %  

 
 

  19.7  

 
 

  %  

 
 

  15.7  

 
 

  %  

 
 

  16.1  

 
 

  %  

 
 
Foreign exchange loss  

632

 
 

 

 
 

227

 
 

 

 
 

460

 
 

 

 
 

404

 
 

 

 
Other expenses  

19

 
 

 

 
 

(35

 
 

)

 
 

22

 
 

 

 
 

3,369

 
 

 

 
Interest expense and other financing costs  

1,409

 
 

 

 
 

1,966

 
 

 

 
 

6,042

 
 

 

 
 

9,372

 
 

 

 
Income before income taxes  

20,674

 
 

 

 
 

18,174

 
 

 

 
 

57,048

 
 

 

 
 

42,304

 
 

 

 
Provision for income taxes  

5,269

 
 

 

 
 

5,011

 
 

 

 
 

15,450

 
 

 

 
 

10,647

 
 

 

 
  Net income   

  15,405  

 
 

 

 
 

  13,163  

 
 

 

 
 

  41,598  

 
 

 

 
 

  31,657  

 
 

 

 
  Adjusted net income   

  17,614  

 
 

 

 
 

  14,253  

 
 

 

 
 

  47,948  

 
 

 

 
 

  38,111  

 
 

 

 
 
  EBITDA   

  25,417  

 
 

 

 
 

  22,902  

 
 

 

 
 

  75,299  

 
 

 

 
 

  62,592  

 
 

 

 
  Adjusted EBITDA   

  29,383  

 
 

 

 
 

  25,641  

 
 

 

 
 

  87,985  

 
 

 

 
 

  75,909  

 
 

 

 
 
  Adjusted EBITDA margin   

  24.4  

 
 

  %  

 
 

  24.8  

 
 

  %  

 
 

  21.8  

 
 

  %  

 
 

  22.0  

 
 

  %  

 
 
  Weighted average number of shares  
Basic  

39,866,189

 
 

 

 
 

38,967,875

 
 

 

 
 

39,539,955

 
 

 

 
 

38,535,274

 
 

 

 
Diluted  

41,487,349

 
 

 

 
 

40,130,698

 
 

 

 
 

41,160,341

 
 

 

 
 

39,614,909

 
 

 

 
 
  Earnings per share attributable to common shareholders:  
Basic, earnings per share  

  0.39  

 
 

 

 
 

  0.34  

 
 

 

 
 

  1.05  

 
 

 

 
 

  0.82  

 
 

 

 
Diluted, earnings per share  

  0.37  

 
 

 

 
 

  0.33  

 
 

 

 
 

  1.01  

 
 

 

 
 

  0.80  

 
 

 

 
Adjusted Diluted, earnings per share  

  0.42  

 
 

 

 
 

  0.36  

 
 

 

 
 

  1.16  

 
 

 

 
 

  0.96  

 
 

 

 
 
                                                                                                                                                                                                         
 

  Jamieson Wellness Inc.  

 

Consolidated Statements of Financial Position

 

In thousands of Canadian dollars

 
 

 

 
 

 

 
  December 31,
2020
 
  December 31,
2019
 
  Assets  
  Current assets  
Cash  

1,166

 
 

 

 
 

198

 
 

 

 
Accounts receivable  

97,951

 
 

 

 
 

89,394

 
 

 

 
Inventories  

102,645

 
 

 

 
 

81,948

 
 

 

 
Prepaid expenses and other current assets  

2,389

 
 

 

 
 

1,893

 
 

 

 
 

  204,151  

 
 

 

 
 

  173,433  

 
 

 

 
  Non-current assets  
Property, plant and equipment  

83,796

 
 

 

 
 

64,906

 
 

 

 
Goodwill  

122,975

 
 

 

 
 

122,975

 
 

 

 
Intangible assets  

196,158

 
 

 

 
 

198,189

 
 

 

 
Deferred income tax  

2,261

 
 

 

 
 

2,272

 
 

 

 
  Total assets   

  609,341  

 
 

 

 
 

  561,775  

 
 

 

 
 
  Liabilities  
  Current liabilities  
Accounts payable and accrued liabilities  

73,084

 
 

 

 
 

67,795

 
 

 

 
Income taxes payable  

6,580

 
 

 

 
 

2,365

 
 

 

 
Derivatives  

8,231

 
 

 

 
 

1,292

 
 

 

 
Current portion of other long-term liabilities  

3,115

 
 

 

 
 

1,890

 
 

 

 
 

  91,010  

 
 

 

 
 

  73,342  

 
 

 

 
  Long-term liabilities  
Long-term debt  

149,058

 
 

 

 
 

164,769

 
 

 

 
Post-retirement benefits  

3,538

 
 

 

 
 

3,923

 
 

 

 
Deferred income tax  

51,479

 
 

 

 
 

51,107

 
 

 

 
Other long-term liabilities  

21,854

 
 

 

 
 

9,466

 
 

 

 
  Total liabilities   

  316,939  

 
 

 

 
 

  302,607  

 
 

 

 
 
  Shareholders' equity  
Share capital  

255,795

 
 

 

 
 

243,224

 
 

 

 
Contributed surplus  

12,986

 
 

 

 
 

10,727

 
 

 

 
Deficit  

29,023

 
 

 

 
 

6,061

 
 

 

 
Accumulated other comprehensive income (loss)  

(5,402

 
 

)

 
 

(844

 
 

)

 
  Total shareholders' equity   

  292,402  

 
 

 

 
 

  259,168  

 
 

 

 
  Total liabilities and shareholders' equity   

  609,341  

 
 

 

 
 

  561,775  

 
 

 

 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
 

  Jamieson Wellness Inc.  

 

Segment Information

 

In thousands of Canadian dollars, except as otherwise noted

 
  Jamieson Brands  
 
  Three months ended
December 31
 
 

  2020  

 
 

  2019  

 
  $ Change    % Change  
 
Revenue  

89,733

 
 

 

 
 

78,803

 
 

 

 
 

10,930

 
 

 

 
 

13.9

 
 

%

 
 

 

 
Gross profit  

38,566

 
 

 

 
 

35,962

 
 

 

 
 

2,604

 
 

 

 
 

7.2

 
 

%

 
Gross profit margin  

43.0

 
 

%

 
 

45.6

 
 

%

 
 

-

 
 

 

 
 

(2.6

 
 

%)

 
 
Selling, general and administrative expenses  

16,906

 
 

 

 
 

16,035

 
 

 

 
 

871

 
 

 

 
 

5.4

 
 

%

 
 
Share-based compensation  

1,156

 
 

 

 
 

1,573

 
 

 

 
 

(417

 
 

)

 
 

(26.5

 
 

%)

 
 
  Earnings from operations   

  20,504  

 
 

 

 
 

  18,354  

 
 

 

 
 

  2,150  

 
 

 

 
 

  11.7  

 
 

  %  

 
  Operating margin   

  22.9  

 
 

  %  

 
 

  23.3  

 
 

  %  

 
 

  -  

 
 

 

 
 

  (0.4  

 
 

  %)  

 
 
  Adjusted EBITDA   

  26,642  

 
 

 

 
 

  23,154  

 
 

 

 
 

  3,488  

 
 

 

 
 

  15.1  

 
 

  %  

 
  Adjusted EBITDA margin   

  29.7  

 
 

  %  

 
 

  29.4  

 
 

  %  

 
 

  -  

 
 

 

 
 

  0.3  

 
 

  %  

 
 
 
  Strategic Partners  
 
  Three months ended
December 31
 
 

  2020  

 
 

  2019  

 
  $ Change    % Change  
 
Revenue  

30,636

 
 

 

 
 

24,450

 
 

 

 
 

6,186

 
 

 

 
 

25.3

 
 

%

 
 
Gross profit  

3,948

 
 

 

 
 

3,580

 
 

 

 
 

368

 
 

 

 
 

10.3

 
 

%

 
Gross profit margin  

12.9

 
 

%

 
 

14.6

 
 

%

 
 

-

 
 

 

 
 

(1.7

 
 

%)

 
 
Selling, general and administrative expenses  

1,718

 
 

 

 
 

1,602

 
 

 

 
 

116

 
 

 

 
 

7.2

 
 

%

 
 
  Earnings from operations   

  2,230  

 
 

 

 
 

  1,978  

 
 

 

 
 

  252  

 
 

 

 
 

  12.7  

 
 

  %  

 
  Operating margin   

  7.3  

 
 

  %  

 
 

  8.1  

 
 

  %  

 
 

  -  

 
 

 

 
 

  (0.8  

 
 

  %)  

 
 
  Adjusted EBITDA   

  2,741  

 
 

 

 
 

  2,487  

 
 

 

 
 

  254  

 
 

 

 
 

  10.2  

 
 

  %  

 
  Adjusted EBITDA margin   

  8.9  

 
 

  %  

 
 

  10.2  

 
 

  %  

 
 

  -  

 
 

 

 
 

  (1.3  

 
 

  %)  

 
 
 
  Jamieson Brands  
 
  Twelve months ended
December 31
 
 

  2020  

 
 

  2019  

 
  $ Change    % Change  
 
Revenue  

316,423

 
 

 

 
 

265,843

 
 

 

 
 

50,580

 
 

 

 
 

19.0

 
 

%

 
 
Gross profit  

133,861

 
 

 

 
 

116,827

 
 

 

 
 

17,034

 
 

 

 
 

14.6

 
 

%

 
Gross profit margin  

42.3

 
 

%

 
 

43.9

 
 

%

 
 

-

 
 

 

 
 

(1.6

 
 

%)

 
 
Selling, general and administrative expenses  

67,169

 
 

 

 
 

62,403

 
 

 

 
 

4,766

 
 

 

 
 

7.6

 
 

%

 
 
Share-based compensation  

4,925

 
 

 

 
 

4,343

 
 

 

 
 

582

 
 

 

 
 

13.4

 
 

%

 
 
  Earnings from operations   

  61,767  

 
 

 

 
 

  50,081  

 
 

 

 
 

  11,686  

 
 

 

 
 

  23.3  

 
 

  %  

 
  Operating margin   

  19.5  

 
 

  %  

 
 

  18.8  

 
 

  %  

 
 

  -  

 
 

 

 
 

  0.7  

 
 

  %  

 
 
  Adjusted EBITDA   

  81,519  

 
 

 

 
 

  67,436  

 
 

 

 
 

  14,083  

 
 

 

 
 

  20.9  

 
 

  %  

 
  Adjusted EBITDA margin   

  25.8  

 
 

  %  

 
 

  25.4  

 
 

  %  

 
 

  -  

 
 

 

 
 

  0.4  

 
 

  %  

 
 
 
  Strategic Partners  
 
  Twelve months ended
December 31
 
 

  2020  

 
 

  2019  

 
  $ Change    % Change  
 
Revenue  

87,238

 
 

 

 
 

79,137

 
 

 

 
 

8,101

 
 

 

 
 

10.2

 
 

%

 
 
Gross profit  

10,895

 
 

 

 
 

12,907

 
 

 

 
 

(2,012

 
 

)

 
 

(15.6

 
 

%)

 
Gross profit margin  

12.5

 
 

%

 
 

16.3

 
 

%

 
 

-

 
 

 

 
 

(3.8

 
 

%)

 
 
Selling, general and administrative expenses  

9,090

 
 

 

 
 

7,539

 
 

 

 
 

1,551

 
 

 

 
 

20.6

 
 

%

 
 
  Earnings from operations   

  1,805  

 
 

 

 
 

  5,368  

 
 

 

 
 

  (3,563  

 
 

  )  

 
 

  (66.4  

 
 

  %)  

 
  Operating margin   

  2.1  

 
 

  %  

 
 

  6.8  

 
 

  %  

 
 

  -  

 
 

 

 
 

  (4.7  

 
 

  %)  

 
 
  Adjusted EBITDA   

  6,466  

 
 

 

 
 

  8,473  

 
 

 

 
 

  (2,007  

 
 

  )  

 
 

  (23.7  

 
 

  %)  

 
  Adjusted EBITDA margin   

  7.4  

 
 

  %  

 
 

  10.7  

 
 

  %  

 
 

  -  

 
 

 

 
 

  (3.3  

 
 

  %)  

 
 

  Non-IFRS Financial Measures  

 

This press release makes reference to certain non‑IFRS measures. Management uses these non‑IFRS financial measures for purposes of comparison to prior periods and development of future projections and earnings growth prospects. This information is also used by management to measure the profitability of ongoing operations and in analyzing the Company's business performance and trends. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of the Company's results of operations from management's perspective. Accordingly, they should not be considered in isolation nor as a substitute for analysis of the Company's financial information reported under IFRS. We use non‑IFRS measures, including "gross profit", "gross profit margin", "operating margin" "EBITDA", "Adjusted EBITDA", "Adjusted EBITDA margin", "Adjusted Net Income" and "Adjusted Diluted Earnings per Share" to provide supplemental measures of the Company's operating performance and thus highlight trends in the Company's core business that may not otherwise be apparent when relying solely on IFRS financial measures. Management also uses non‑IFRS measures in order to prepare annual operating budgets and to determine components of management compensation. Definitions of non-IFRS measures can be found in the Company's MD&A.

 
                                                                                                                                                                         
 

  Reconciliation of Adjusted Net Income  

 

In thousands of Canadian dollars

 
 
  Three months ended    For the year ended  
  December 31    December 31  
 

  2020  

 
 

  2019  

 
 

  2020  

 
 

  2019  

 
 
  Net income   

  15,405  

 
 

 

 
 

  13,163  

 
 

 

 
 

  41,598  

 
 

 

 
 

  31,657  

 
 

 

 
  Adjustments to net income:  
Share-based compensation  

144

 
 

 

 
 

190

 
 

 

 
 

576

 
 

 

 
 

761

 
 

 

 
Foreign exchange loss  

632

 
 

 

 
 

227

 
 

 

 
 

460

 
 

 

 
 

404

 
 

 

 
Termination benefits and related costs  

-

 
 

 

 
 

-

 
 

 

 
 

-

 
 

 

 
 

480

 
 

 

 
International market expansion  

-

 
 

 

 
 

278

 
 

 

 
 

13

 
 

 

 
 

1,712

 
 

 

 
Business integration  

1,759

 
 

 

 
 

523

 
 

 

 
 

2,299

 
 

 

 
 

1,415

 
 

 

 
COVID-19 related costs  

402

 
 

 

 
 

-

 
 

 

 
 

5,064

 
 

 

 
 

-

 
 

 

 
Other  

17

 
 

 

 
 

196

 
 

 

 
 

22

 
 

 

 
 

5,138

 
 

 

 
Revaluation of deferred tax liability  

-

 
 

 

 
 

-

 
 

 

 
 

-

 
 

 

 
 

(1,032

 
 

)

 
Related tax effects  

(745

 
 

)

 
 

(324

 
 

)

 
 

(2,084

 
 

)

 
 

(2,424

 
 

)

 
  Adjusted net income   

  17,614  

 
 

 

 
 

  14,253  

 
 

 

 
 

  47,948  

 
 

 

 
 

  38,111  

 
 

 

 
 
                                                                                                                                                                     
 

  Reconciliation of EBITDA and Adjusted EBITDA  

 

In thousands of Canadian dollars

 
 
  Three months ended    For the year ended  
  December 31    December 31  
 

  2020  

 
 

  2019  

 
 

  2020  

 
 

  2019  

 
 
  Net income   

  15,405  

 
 

  13,163  

 
 

  41,598  

 
 

  31,657  

 
  Add:  
Provision for income taxes  

5,269

 
 

5,011

 
 

15,450

 
 

10,647

 
Interest expense and other financing costs  

1,409

 
 

1,966

 
 

6,042

 
 

9,372

 
Depreciation of property, plant, and equipment  

2,336

 
 

1,845

 
 

8,260

 
 

7,263

 
Amortization of intangible assets  

998

 
 

917

 
 

3,949

 
 

3,653

 
 
  Earnings before interest, taxes, depreciation, and amortization (EBITDA)   

  25,417  

 
 

  22,902  

 
 

  75,299  

 
 

  62,592  

 
  Add EBITDA adjustments:  
Share-based compensation  

1,156

 
 

1,573

 
 

4,925

 
 

4,343

 
Foreign exchange loss  

632

 
 

227

 
 

460

 
 

404

 
Termination benefits and related costs  

-

 
 

-

 
 

-

 
 

480

 
International market expansion  

-

 
 

278

 
 

13

 
 

1,712

 
Business integration  

1,759

 
 

465

 
 

2,202

 
 

1,240

 
COVID-19 related costs  

402

 
 

-

 
 

5,064

 
 

-

 
Other  

17

 
 

196

 
 

22

 
 

5,138

 
  Adjusted EBITDA   

  29,383  

 
 

  25,641  

 
 

  87,985  

 
 

  75,909  

 
 

 

 

  

  

  Investor and Media Contact Information:  
Jamieson Wellness
Ruth Winker
416-705-5437
rwinker@jamiesonlabs.com  

 

News Provided by Business Wire via QuoteMedia

The Conversation (0)
Various blister packs with pills and capsules in different colors and shapes.

Trump Signs Sweeping Order to Slash Drug Prices, Pressure Pharma Giants

US President Donald Trump has signed a sweeping executive order aimed at dramatically reducing prices for prescription drugs, vowing to end “foreign free-riding” on American pharmaceutical innovation.

The order directs federal agencies to pressure both drug manufacturers and wealthy foreign countries to bring their prices in line with those paid in the US, or face aggressive trade and regulatory actions.

“In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism abroad with skyrocketing prices at home,” Trump states in the order.

Keep reading...Show less
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2025

The global pharmaceutical market reached a total value of US$1.38 trillion in 2024, according to Research and Markets, up significantly from the US$888 billion seen just over a decade earlier in 2010.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

The main advantage of a pharmaceutical ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

Keep reading...Show less
Invion Limited

Invion Limited

Keep reading...Show less
Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

Top 5 Small-cap Pharma Stocks in 2025

Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval.

However, the industry's major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected to dissipate.

The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2024, 50 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 55 such approvals in 2023. Last year's FDA approvals include Eli Lilly and Company's (NYSE:LLY) Alzheimer's disease treatment Kisunla.

Big pharma largely steals the show, but some small- and mid-cap NASDAQ pharma stocks have also made gains.

Keep reading...Show less
Cardiol Therapeutics (TSX:CRDL)

Cardiol Therapeutics Announces Year-End 2024 Update on Operations

Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trial

Completed patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patients
with acute myocarditis, with topline data expected in Q2 2025

Keep reading...Show less

Latest Press Releases

Related News

×